CClinicalTrials.gg
CompletedNCT05237778Updated Feb 14, 2022

Combined Treatment of Nightmares With Targeted Memory Reactivation and Imagery Rehearsal Therapy

An interventional study of Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep and Imagery Rehearsal Therapy in Nightmares, REM-Sleep Type, sponsored by University Hospital, Geneva. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-02-14.

Sponsored by University Hospital, Geneva · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Feb 2020, registered Feb 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

With this protocol, investigators examine whether targeted memory reactivation (TMR), a technique used to strengthen memories, can accelerate remission of nightmare disorder. This protocol uses TMR during REM sleep to strengthen positive memories generated by Imagery Rehearsal Therapy (IRT), a recommended treatment of nightmares. Patients with nightmare disorder are asked to perform an initial IRT session and, while they generate a positive outcome of their recurrent nightmare, half of the patients are exposed to a sound (TMR group), while no such pairing with a sound takes place for the other half (control group). During the next two weeks, all patients perform IRT every evening at home and are exposed to the sound during REM sleep with a wireless headband, which automatically detects sleep stages. Clinical evaluation of the severity of nightmares before and after (2-weeks follow-up and 3-months follow-up) this intervention takes place using the validated Nightmare Frequency Questionnaire (NFQ, primary outcome measure), which retrospectively identifies the frequency of nightmares. We hypothesize that patients treated with IRT and who are exposed, during REM sleep and over 14 nights, to a sound that had previously been associated with the new positive dream scenario of IRT (TMR group), will have more reduced frequency of nightmares compared to participants with stimulation of the same, but non-associated, sound during REM sleep (control group).

02

Conditions studied

  • Nightmares, REM-Sleep Type
03

In context

Lead sponsor

University Hospital, Geneva is the lead sponsor of 372 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of nightmare disorder according to the International Classification of Sleep Disorders (ICSD-3) diagnostic and coding manual
  • Patients with at least moderate severity (>1 episode per week)

Exclusion criteria

Exclusion Criteria:

  • severe depression
  • insomnia disorder
  • psychosis or anxiety disorder
  • other sleep disorder (e.g.,obstructive sleep apnea syndrome, restless legs syndrome)
  • neurological disease
  • use of medications that would be likely to produce nightmares (e.g. hypnotics, β-blockers, amphetamines, antimicrobial agents)
  • use of anxiolytics, antipsychotic or antidepressant medication were excluded.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    TMR group

    Patients will receive a sound while they generate a positive outcome of imagery rehearsal therapy (IRT). They will also receive the sound during REM sleep.

    Behavioral: Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep

  • Active comparator
    Control group

    Patients will not receive a sound while they generate a positive outcome of imagery rehearsal therapy (IRT). They will receive the same sound as the experimental group during REM sleep under the same conditions.

    Behavioral: Imagery Rehearsal Therapy

Interventions

  • BehavioralImagery Rehearsal Therapy and Targeted memory reactivation during REM sleep

    Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where we associate a sound with a waking experience (i.e., a positive outcome of imagery rehearsal therapy in this study) and strengthening it during REM sleep, we want to accelerate the remission of nightmares.

  • BehavioralImagery Rehearsal Therapy

    These patients will receive the classic treatment of Imagery Rehearsal Therapy (IRT) for nightmares without any association with a sound.

06

What researchers measure

Primary outcomes

  1. Nightmare Frequency Questionnaire (NFQ)

    Validated self-report scale to assess the number of nightmares per week

    Time frame: 2 weeks

  2. Nightmare Frequency Questionnaire (NFQ)

    Validated self-report scale to assess the number of nightmares per week

    Time frame: 3 months

Secondary outcomes

  1. Nightmare Distress Questionnaire (NDQ)

    Validated self-report scale to assess the emotional disturbance attributed to the nightmares

    Time frame: 2 weeks

  2. Beck Depression Inventory (BDI-II)

    Validated self-report scale to assess depressive symptoms

    Time frame: 2 weeks

  3. Pittsburgh Sleep Quality Index (PSQI)

    Validated self-report scale to assess the quality of sleep

    Time frame: 2 weeks

  4. Proportion of the emotion 'joy' in dreams

    Use of a dream diary

    Time frame: 2 weeks

  5. Proportion of the emotion 'fear' in dreams

    Use of a dream diary

    Time frame: 2 weeks

  6. Nightmare Distress Questionnaire (NDQ)

    Validated self-report scale to assess the emotional disturbance attributed to the nightmares

    Time frame: 3 months

  7. Beck Depression Inventory (BDI-II)

    Validated self-report scale to assess depressive symptoms

    Time frame: 3 months

  8. Pittsburgh Sleep Quality Index (PSQI)

    Validated self-report scale to assess the quality of sleep

    Time frame: 3 months

07

Study locations

1 site
  • Center for Sleep Medicine, University Hospitals of Geneva
    Geneva, 1225, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05237778
Lead sponsor
University Hospital, Geneva
Responsible party
Lampros Perogamvros (Senior Clinical Fellow, University Hospital, Geneva) — Principal investigator
First posted
Feb 14, 2022
Start date
Feb 1, 2020
Primary completion
Jan 31, 2022
Completion
Jan 31, 2022
Last update
Feb 14, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion